These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24255981)

  • 1. A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course.
    Rizzieri D; Vey N; Thomas X; Huguet-Rigal F; Schlenk RF; Krauter J; Kindler T; Gjertsen BT; Blau IW; Jacobsen TF; Johansen M; Bergeland T; Gianella-Borradori A; Krug U
    Leuk Lymphoma; 2014 Sep; 55(9):2114-9. PubMed ID: 24255981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.
    Candelaria M; Corrales-Alfaro C; Gutiérrez-Hernández O; Díaz-Chavez J; Labardini-Méndez J; Vidal-Millán S; Herrera LA
    Chemotherapy; 2016; 61(6):313-8. PubMed ID: 27119162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical potential of elacytarabine in patients with acute myeloid leukemia.
    Rein LA; Rizzieri DA
    Ther Adv Hematol; 2014 Dec; 5(6):211-20. PubMed ID: 25469211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.
    Giles F; Rizzieri D; Ravandi F; Swords R; Jacobsen TF; O'Brien S
    Leuk Res; 2012 Apr; 36(4):e71-3. PubMed ID: 22226018
    [No Abstract]   [Full Text] [Related]  

  • 5. Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.
    O'Brien S; Rizzieri DA; Vey N; Ravandi F; Krug UO; Sekeres MA; Dennis M; Venditti A; Berry DA; Jacobsen TF; Staudacher K; Bergeland T; Giles FJ
    Br J Haematol; 2012 Sep; 158(5):581-8. PubMed ID: 22702906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.
    DiNardo CD; O'Brien S; Gandhi VV; Ravandi F
    Future Oncol; 2013 Aug; 9(8):1073-82. PubMed ID: 23902239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia.
    Català A; Pastor-Anglada M; Caviedes-Cárdenas L; Malatesta R; Rives S; Vega-García N; Camós M; Fernández-Calotti P
    Oncotarget; 2016 Aug; 7(31):49786-49799. PubMed ID: 27391351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia.
    Jaramillo AC; Hubeek I; Broekhuizen R; Pastor-Anglada M; Kaspers GJL; Jansen G; Cloos J; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(10-12):1379-1388. PubMed ID: 32312148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia].
    Qian SX; Li JY; Wu HX; Lu H; Qiu HX; Chen LJ; Lu RN; Xu W; Sheng RL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):209-13. PubMed ID: 19236781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
    Guolo F; Minetto P; Clavio M; Miglino M; Di Grazia C; Ballerini F; Pastori G; Guardo D; Colombo N; Kunkl A; Fugazza G; Rebesco B; Sessarego M; Lemoli RM; Bacigalupo A; Gobbi M
    Am J Hematol; 2016 Aug; 91(8):755-62. PubMed ID: 27084986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells.
    Hummel-Eisenbeiss J; Hascher A; Hals PA; Sandvold ML; Müller-Tidow C; Lyko F; Rius M
    Mol Pharmacol; 2013 Sep; 84(3):438-50. PubMed ID: 23814180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial).
    Krauter J; Fiedler W; Schlenk RF; Paschka P; Thol F; Lübbert M; Wattad M; Verbeek M; Könecke C; Neuhaus B; Papkalla A; Kebenko M; Janning M; Döhner K; Gaidzik VI; Becker H; Greil C; Reimer P; Götze KS; Döhner H; Ganser A; Heuser M
    Br J Haematol; 2018 Oct; 183(2):235-241. PubMed ID: 30378121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile.
    Knapper S; Chevassut T; Duarte R; Bergua JM; Salamero O; Johansen M; Jacobsen TF; Hals PA; Rasch W; Gianella-Borradori A; Smith M
    Leuk Res; 2014 Mar; 38(3):346-51. PubMed ID: 24433865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
    Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
    Martínez-Cuadrón D; Gil C; Serrano J; Rodríguez G; Pérez-Oteyza J; García-Boyero R; Jiménez-Bravo S; Vives S; Vidriales MB; Lavilla E; Pérez-Simón JA; Tormo M; Colorado M; Bergua J; López JA; Herrera P; Hernández-Campo P; Gorrochategui J; Primo D; Rojas JL; Villoria J; Moscardó F; Troconiz I; Linares Gómez M; Martínez-López J; Ballesteros J; Sanz M; Montesinos P;
    Leuk Res; 2019 Jan; 76():1-10. PubMed ID: 30468991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
    Kim I; Koh Y; Yoon SS; Park S; Kim BK; Kim DY; Lee JH; Lee KH; Cheong JW; Lee HK; Kim SH; Kim H; Joo YD; Lee SM; Won JH; Park SK; Hong DS; Kim SH; Sohn SK; Kim CS; Park E; Kim MK; Park MR; Lee JH; Min YH;
    Am J Hematol; 2013 Jan; 88(1):10-5. PubMed ID: 23077109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
    Low M; Lee D; Coutsouvelis J; Patil S; Opat S; Walker P; Schwarer A; Salem H; Avery S; Spencer A; Wei A
    Intern Med J; 2013 Mar; 43(3):294-7. PubMed ID: 22757980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.
    Roboz GJ; Rosenblat T; Arellano M; Gobbi M; Altman JK; Montesinos P; O'Connell C; Solomon SR; Pigneux A; Vey N; Hills R; Jacobsen TF; Gianella-Borradori A; Foss Ø; Vetrhusand S; Giles FJ
    J Clin Oncol; 2014 Jun; 32(18):1919-26. PubMed ID: 24841975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
    de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F
    Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.